LOS ANGELES , Aug. 12, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development...
FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meeting
Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patients
Entered into secured credit agreement with Innoviva for $25 million maturing in 2029
Enables more frequent FDA engagement, rolling Biologic License Application review, and the potential for Accelerated Approval and Priority Review upon successful clinical development
Describes structure of phage P7-1, included in Armata's Pseudomonas aeruginosa phage cocktail, AP-PA02
LOS ANGELES , April 27, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development...
LOS ANGELES , March 25, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development...
Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus
FDA agreed that data from the Phase 2a diSArm study support advancement of AP-SA02 to a Phase 3 study